Skip to content

McKesson MCK Current Debt

Current Debt at other companies

Eli Lilly logo
Eli LillyLLY
$4B-0.4%
AbbVie logo
AbbVieABBV
$0-100%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$6.2M-80.5%
Viatris logo
ViatrisVTRS
$1.93B+22,619%
The Oncology Institute, Inc. logo
The Oncology Institute, Inc.TOI
$36K0.0%
Medline, Inc.
 logo
Medline, Inc. MDLN
$1M

Other financials

Income statement

See full
Revenue$96.3B+6.0%
Gross profit$4.0B+11.1%
Operating income$2.2B+35.1%
Net income$1.7B+33.5%
EPS (diluted)$13.65+37.6%

Balance sheet

See full
Cash & equivalents$4.0B-33.3%
Total debt$2.3B-74.2%
Total equity-$2.2B-4.7%
Total assets$82.3B+9.6%

Cash flow

See full
Operating cash flow$3.4B-55.8%
CapEx$111.0M-34.3%
Free cash flow$3.3B-56.3%

Valuation

See full
Market cap$104.14B+17.1%
Enterprise value$102.44B+5.1%
P/E21.9×-6.2×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%-0.1pp
Operating margin1.5%+0.3pp
Net margin1.2%+0.3pp
FCF margin1.4%-0.1pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent.

The official record: McKesson’s 10-Q, filed February 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about McKesson's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is McKesson's current debt?
McKesson (MCK) reported current debt of $1.13B in Q4 2025.
How has McKesson's current debt changed year-over-year?
McKesson's current debt decreased by 53.3% year-over-year, from $2.43B to $1.13B.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.